Effect of supplementation in treatment of cervical intraepithelial neoplasia 1

The effect of vitamin D supplementation on treatment, metabolic profiles and hs-CRP in women with cervical intraepithelial neoplasia 1(CIN1)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201412065623N30

Enrollment

Registered

2014-12-19

Start date

2014-08-06

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical intraepithelial neoplasia 1(CIN1). Cervix uteri, unspecified

Interventions

Intervention 1: Intervention group: Vitamin D pearl, 50000 IU (Zahravi, Tabriz, Iran), every 2 weeks, for 6 months orally. Intervention 2: Control group: Placebo pearl (Barij Essence, Kashan, Iran), e

Eligibility

Sex/Gender

Female

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Women aged 18-55 years Diagnosed with cervical intraepithelial neoplasia 1

Exclusion criteria

Exclusion criteria: Women who had a history of cervical cancer or other cancers of the lower genital tract History of hysterectomy or destructive therapy of the cervix Pregnant women

Design outcomes

Primary

Measure	Time frame
Cervical intraepithelial neoplasia grade. Timepoint: Baseline and End-of-trial. Method of measurement: Colposcopic.	—

Secondary

Measure	Time frame
Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Calculation using HOMA formula.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive Protein. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Serum vitamin D. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.	—

Measure

Time frame

Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Calculation using HOMA formula.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive Protein. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Serum vitamin D. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_r@yahoo.com+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 11, 2026